Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
Jacqueline S. Garcia(Dana-Farber Cancer Institute), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Uma Borate(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Wan‐Jen Hong, Rajesh Kamalakar(AbbVie (United States)), Maria R. Baer(University of Maryland, Baltimore), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre), Joseph G. Jurcic(Memorial Sloan Kettering Cancer Center), Jessica E. Hutti(AbbVie (United States)), Florian Nolte(Heidelberg University), Bo Tong(AbbVie (United States)), Olatoyosi Odenike(University of Chicago), Ying Zhou(Tongji University), Leah J. Hogdal(Harvard University), Steve Kye(AbbVie (United States)), Uwe Platzbecker(National Center for Tumor Diseases), Ilona Cunningham(The University of Sydney), Meagan A. Jacoby(MACOM (United States)), Andrew H. Wei(The Royal Melbourne Hospital)
Cited by 58
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k